Christopher Major, Director of Oncology Diagnostics at Janssen Pharmaceuticals R&D, received his PhD in Cell and Molecular Biology from the University of Pennsylvania. He completed post-doctoral fellowships at the National Cancer Institute and Johnson and Johnson Pharmaceutical Research & Development. He joined Janssen Pharmaceutical R&D in 2011 and has directed companion and complementary diagnostic development in support of Janssen therapeutic compounds. In 2017 he joined the Janssen Oncology Diagnostic group as Scientific Director, developing the companion diagnostic strategy for multiple oncology programs, providing oversight of all diagnostic development activities in support of the oncology portfolio at Janssen Pharmaceuticals.
Chris has over 15 years’ experience in the pharmaceutical and medical diagnostic industries, bringing expertise in development of in vitro diagnostic assays and companion diagnostics in accordance with global regulations. He has collaborated on NSRs, IDEs, Pre-Subs, & PMAs with IVD partners as well as participated in regulatory interactions with FDA, CFDA, and PMDA. His mission is to ensure the first Janssen drug-companion diagnostic submission to FDA in 2018.